Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (320) 320
humans (287) 287
male (218) 218
gastroenterology & hepatology (215) 215
female (212) 212
adult (186) 186
middle aged (174) 174
hepatitis c, chronic - drug therapy (106) 106
antiviral agents - therapeutic use (94) 94
hepatitis c (91) 91
aged (83) 83
treatment outcome (83) 83
genotype (82) 82
drug therapy, combination (80) 80
gastroenterology and hepatology (76) 76
interferon-alpha - therapeutic use (69) 69
hepacivirus - genetics (66) 66
ribavirin - therapeutic use (66) 66
ribavirin (65) 65
interferon (60) 60
hepatitis c virus (56) 56
polyethylene glycols - therapeutic use (56) 56
adolescent (55) 55
therapy (48) 48
recombinant proteins (47) 47
abridged index medicus (46) 46
care and treatment (45) 45
hepatitis (44) 44
virus-infection (43) 43
viral load (42) 42
genetic aspects (40) 40
antiviral agents - administration & dosage (39) 39
cirrhosis (39) 39
hepatitis c, chronic - virology (39) 39
liver (39) 39
interferon-alpha - administration & dosage (37) 37
ribavirin - administration & dosage (37) 37
young adult (37) 37
rna, viral - blood (36) 36
analysis (35) 35
mutation (35) 35
chronic hepatitis-c (34) 34
diagnosis (34) 34
health aspects (34) 34
hepatolenticular degeneration - genetics (33) 33
medicine, general & internal (33) 33
hepacivirus - drug effects (32) 32
liver - pathology (32) 32
retrospective studies (32) 32
sustained virological response (31) 31
antiviral agents - adverse effects (30) 30
follow-up studies (30) 30
hepatitis c, chronic - complications (30) 30
plus ribavirin (30) 30
prospective studies (29) 29
recombinant proteins - therapeutic use (29) 29
animals (28) 28
infectious diseases (28) 28
ribavirin - adverse effects (28) 28
infection (27) 27
liver cirrhosis (27) 27
prognosis (27) 27
human necessities (26) 26
hygiene (26) 26
polyethylene glycols - administration & dosage (26) 26
time factors (26) 26
child (25) 25
chronic hepatitis c (25) 25
hepatolenticular degeneration - diagnosis (25) 25
interferon-alpha - adverse effects (25) 25
medical or veterinary science (25) 25
pharmacology & pharmacy (25) 25
predictive value of tests (25) 25
preparations for medical, dental, or toilet purposes (25) 25
virology (25) 25
biological response modifiers (24) 24
liver transplantation (24) 24
interleukins - genetics (23) 23
liver - metabolism (23) 23
specific therapeutic activity of chemical compounds ormedicinal preparations (23) 23
drug therapy (22) 22
gene (22) 22
hepatitis c - drug therapy (22) 22
medical colleges (22) 22
peginterferon alpha-2a (22) 22
adenosine triphosphatases - genetics (21) 21
antiviral agents (21) 21
combination therapy (21) 21
copper (21) 21
dose-response relationship, drug (21) 21
hepacivirus - isolation & purification (21) 21
liver diseases (21) 21
polymerase chain reaction (21) 21
recurrence (21) 21
risk factors (21) 21
telaprevir (21) 21
biopsy (20) 20
copper - metabolism (20) 20
copper-transporting atpases (20) 20
genotype & phenotype (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (587) 587
German (22) 22
French (16) 16
Hungarian (11) 11
Spanish (4) 4
Slovak (3) 3
Polish (2) 2
Danish (1) 1
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phenotype–genotype correlations in patients with Wilson's disease
by Ferenci, Peter
Annals of the New York Academy of Sciences, ISSN 0077-8923, 05/2014, Volume 1315, Issue 1, pp. 1 - 5
There is considerable phenotypic variation in Wilson's disease (WD). Some patients present with hepatic disease during the first decade of life and some with... 
movement disorders | ATP7B mutations | liver disease | Wilson's disease | Movement disorders | Liver disease | DIAGNOSIS | PHYSIOLOGY | SIBLINGS | CONCORDANCE | ATP7B | GENE | STEATOSIS | MUTATION | ENDOCRINOLOGY & METABOLISM | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | EXPRESSION | ONSET | Genetic Association Studies | Copper-transporting ATPases | Humans | Middle Aged | Hepatolenticular Degeneration - diagnosis | Male | Delayed Diagnosis | Young Adult | Adolescent | Age of Onset | Copper - metabolism | Adult | Cation Transport Proteins - genetics | Female | Adenosine Triphosphatases - genetics | Hepatolenticular Degeneration - genetics | Mutation | Copper - toxicity | Child | Hepatolenticular Degeneration - metabolism | Siblings | Genotype & phenotype | Medical research | Liver diseases | Child development | Index Medicus | Correlation | Toxicity | Liver | Central nervous system | Genetics | Degeneration | Disease control | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text New anti-HCV drug combinations: who will benefit?
by Ferenci, Peter
The Lancet Infectious Diseases, ISSN 1473-3099, 10/2017, Volume 17, Issue 10, pp. 1008 - 1009
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/S1473-3099(17)30486-3 Byline: Peter Ferenci (a) 
INFECTIOUS DISEASES | SOFOSBUVIR | Hepatitis C virus | Drug therapy, Combination | Antiretroviral drugs | Genotype & phenotype | Hepatitis | Liver diseases | Gastroenterology | Infections | Interferon | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phenotype-genotype correlations in patients with Wilson's disease
: Phenotype-genotype correlation
by Ferenci, Peter
Annals of the New York Academy of Sciences, ISSN 0077-8923, 05/2014, Volume 1315, Issue 1, pp. 1 - 5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Silymarin in the treatment of liver diseases: What is the clinical evidence?
by Ferenci, Peter
Clinical Liver Disease, ISSN 2046-2484, 01/2016, Volume 7, Issue 1, pp. 8 - 10
Watch a video presentation of this article Watch the interview with the author 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cure of chronic hepatitis C—required length of follow-up?
by Ferenci, Peter
Nature Reviews Gastroenterology & Hepatology, ISSN 1759-5045, 01/2015, Volume 12, Issue 1, pp. 10 - 11
The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir-ribavirin with or... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Wilson's disease: Fatal when overlooked, curable when diagnosed
by Ferenci, Peter and Ott, Peter
Journal of Hepatology, ISSN 0168-8278, 07/2019, Volume 71, Issue 1, pp. 222 - 224
Copper metabolism | Liver histology | COPPER | Wilson disease | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
by Vilstrup, Hendrik and Amodio, Piero and Bajaj, Jasmohan and Cordoba, Juan and Ferenci, Peter and Mullen, Kevin D and Weissenborn, Karin and Wong, Philip
Hepatology, ISSN 0270-9139, 08/2014, Volume 60, Issue 2, pp. 715 - 735
The AASLD/EASL Practice Guideline Subcommittee on Hepatic Encephalopathy are: Jayant A. Talwalkar (Chair, AASLD), Hari S. Conjeevaram, Michael Porayko, Raphael... 
CRITICAL FLICKER FREQUENCY | MAGNETIC-RESONANCE-SPECTROSCOPY | INTRAHEPATIC PORTOSYSTEMIC SHUNT | NUMBER CONNECTION TEST | PRIMARY BILIARY-CIRRHOSIS | ISHEN PRACTICE GUIDELINES | CHAIN AMINO-ACIDS | RANDOMIZED CONTROLLED-TRIAL | QUALITY-OF-LIFE | PORTAL-SYSTEMIC ENCEPHALOPATHY | GASTROENTEROLOGY & HEPATOLOGY | Hepatic Encephalopathy - therapy | United States | Europe | Humans | Hepatic Encephalopathy - diagnosis | Liver Diseases - therapy | Liver Diseases - diagnosis | Liver Diseases - epidemiology | Chronic Disease | Hepatic Encephalopathy - epidemiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Diagnosis of minimal hepatic encephalopathy: still a challenge
by Ferenci, Peter
Gut, ISSN 0017-5749, 10/2013, Volume 62, Issue 10, pp. 1394 - 1394
NUMBER-CONNECTION TESTS | Cirrhosis | PSYCHOMETRIC TESTS | GASTROENTEROLOGY & HEPATOLOGY | Hepatic Encephalopathy | Hepatic Encephalopathy - diagnosis | Female | Male | Liver Transplantation | Humans | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease
by Ferenci, Peter and Stremmel, Wolfgang and Członkowska, Anna and Szalay, Ferenc and Viveiros, André and Stättermayer, Albert Friedrich and Bruha, Radan and Houwen, Roderick and Pop, Tudor Lucian and Stauber, Rudolf and Gschwantler, Michael and Pfeiffenberger, Jan and Yurdaydin, Cihan and Aigner, Elmar and Steindl‐Munda, Petra and Dienes, Hans‐Peter and Zoller, Heinz and Weiss, Karl Heinz
Hepatology, ISSN 0270-9139, 04/2019, Volume 69, Issue 4, pp. 1464 - 1476
Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being... 
Adolescence | Phenotypes | Liver diseases | Nucleotide sequence | Mental disorders | Neurological diseases | Cirrhosis | Gene frequency | Biopsy | Children | Mutation | Diagnosis | Females | Wilson's disease | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Viral hepatitis : Cure of chronic hepatitis C-required length of follow-up?
by Ferenci, Peter
Nature Reviews Gastroenterology and Hepatology, ISSN 1759-5045, 01/2015, Volume 12, Issue 1, pp. 10 - 11
The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir-ribavirin with or... 
SUSTAINED VIROLOGICAL RESPONSE | VIRUS | THERAPY | SOFOSBUVIR | INFECTION | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Continuity of Patient Care | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Remission Induction | Uridine Monophosphate - analogs & derivatives | Hepatitis C, Chronic - genetics | Sofosbuvir | Uridine Monophosphate - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
by Zeuzem, Stefan and Dusheiko, Geoffrey M and Salupere, Riina and Mangia, Alessandra and Flisiak, Robert and Hyland, Robert H and Illeperuma, Ari and Svarovskaia, Evguenia and Brainard, Diana M and Symonds, William T and Subramanian, G. Mani and McHutchison, John G and Weiland, Ola and Reesink, Hendrik W and Ferenci, Peter and Hézode, Christophe and Esteban, Rafael and VALENCE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1993 - 2001
In patients with HCV genotypes 2 and 3, sofosbuvir plus ribavirin was administered for 12 weeks in patients with genotype 2 and for 24 weeks in those with... 
SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | THERAPIES | FUTURE | HEPATITIS-C | C VIRUS-INFECTION | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | RNA, Viral - blood | Hepatitis C, Chronic - drug therapy | Viral Load | Drug Resistance, Viral - genetics | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adult | Female | Aged | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use | Evaluation | Usage | Care and treatment | Safety and security measures | Clinical trials | Hepatitis C | Comparative analysis | Ribavirin | Headache | Fatigue | Infections | Pruritus | Patients | Cirrhosis | Genotype & phenotype | Hepatitis | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Assaigs clínics | Antiviral agents | Terapèutica | Therapeutics | Medicaments antivírics | Farmacologia | Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Hepatic encephalopathy
by Ferenci, Peter
Gastroenterology Report, 5/2017, Volume 5, Issue 2, pp. 138 - 147
Hepatic encephalopathy (HE) is a reversible syndrome of impaired brain function occurring in patients with advanced liver diseases. The precise pathophysiology... 
diagnostic tests | management strategy | pathophysiology | Review | Hepatic encephalopathy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text EASL Clinical Practice Guidelines: Wilson's disease
by Ferenci, Peter and Czlonkowska, Anna and Stremmel, Wolfgang and Houwen, Roderick and Rosenberg, William and Schilsky, Michael and Jansen, Peter and Moradpour, Darius and Gitlin, Jonathan and European Assoc Study Liver and European Association for Study of Liver
Journal of Hepatology, ISSN 0168-8278, 03/2012, Volume 56, Issue 3, pp. 671 - 685
This Clinical Practice Guideline (CPG) has been developed to assist physicians and other healthcare providers in the diagnosis and management of patients with... 
ACUTE LIVER-FAILURE | MUTATION ANALYSIS | AMMONIUM TETRATHIOMOLYBDATE | HEPATIC COPPER | URINARY COPPER EXCRETION | DIAGNOSTIC-CRITERIA | JAPANESE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | LONG-TERM TREATMENT | D-PENICILLAMINE | EVOKED-POTENTIALS | Hepatolenticular Degeneration - diagnosis | Liver Diseases - therapy | Liver Diseases - diagnosis | Hepatolenticular Degeneration - therapy | Gastroenterology - standards | Humans | Practice guidelines (Medicine) | Wilson's disease | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Treatment With Silymarin for Hepatitis C Virus
by Ferenci, Peter
JAMA, ISSN 0098-7484, 11/2012, Volume 308, Issue 18, pp. 1856 - 1857
MEDICINE, GENERAL & INTERNAL | THERAPY | RANDOMIZED CONTROLLED-TRIAL | LIVER-DISEASE | CIRRHOSIS | Alanine Transaminase - drug effects | Hepatitis C, Chronic - enzymology | Humans | Antioxidants - administration & dosage | Female | Male | Hepatitis C, Chronic - drug therapy | Silymarin - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
by Ferenci, Peter and Bernstein, David and Lalezari, Jacob and Cohen, Daniel and Luo, Yan and Cooper, Curtis and Tam, Edward and Marinho, Rui T and Tsai, Naoky and Nyberg, Anders and Box, Terry D and Younes, Ziad and Enayati, Pedram and Green, Sinikka and Baruch, Yaacov and Bhandari, Bal Raj and Caruntu, Florin Alexandru and Sepe, Thomas and Chulanov, Vladimir and Janczewska, Ewa and Rizzardini, Giuliano and Gervain, Judit and Planas, Ramon and Moreno, Christophe and Hassanein, Tarek and Xie, Wangang and King, Martin and Podsadecki, Thomas and Reddy, K. Rajender and PEARL-IV Study and PEARL-III Study
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Among previously untreated patients with HCV genotype 1 infection, three new antiviral agents, with or without ribavirin, resulted in high rates of sustained... 
ANTIVIRAL AGENTS | MEDICINE, GENERAL & INTERNAL | INTERFERON | TREATMENT-NAIVE | TELAPREVIR | SOFOSBUVIR | 1 HEPATITIS-C | BOCEPREVIR | DACLATASVIR | COMBINATION | PEGINTERFERON | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Hemoglobins - analysis | Evaluation | Usage | Care and treatment | Safety and security measures | Clinical trials | Hepatitis C | Ribavirin | Headache | Ritonavir | Body weight | Fatigue | Infections | Nausea | Ribonucleic acid--RNA | Patients | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
by Jacobson, Ira M and McHutchison, John G and Dusheiko, Geoffrey and Di Bisceglie, Adrian M and Reddy, K. Rajender and Bzowej, Natalie H and Marcellin, Patrick and Muir, Andrew J and Ferenci, Peter and Flisiak, Robert and George, Jacob and George, Shelley and Rizzetto, Mario and Shouval, Daniel and Sola, Ricard and Terg, Ruben A and Yoshida, Eric M and Adda, Nathalie and Bengtsson, Leif and Sankoh, Abdul J and Kieffer, Tara L and Kauffman, Robert S and M.D, Stefan Zeuzem and ADVANCE Study Team
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights